Abemaciclib (Verzenio) – LY2835219

Preference will be given to studies with requests for material only support.

In scope:

• A limited number of studies answering important medical questions related to HR+/HER2- Breast Cancer that support current indications of abemaciclib will be considered. Proposal must be unique from past or current studies.

Out of scope:

• Any area outside HR+/HER2- breast cancer.
• Study with primary endpoint beyond 2 years from study approval.